Trader and analyst briefing and webcast ARIAD management will host a conference call and webcast to go over these actions today, October 9, at 8:30 a.m. ET. The live webcast can be accessed at the investor relations portion of the Company's website at The decision could be accessed by dialing 299-8538 or +1 786-2902 and offering the participant code 20840481. A replay of the call will be available on the ARIAD site approximately two hours after completion of the decision and you will be archived for three weeks. Information for individuals and physicians To find out more about the noticeable changes in Iclusig medical trials, patients and physicians should www visit.clinicaltrials.gov, call the ARIAD U.S. Toll-free quantity 552-7423, the EU toll-free number 800 00027423, or the worldwide number +1 -503-7423.All analyses were executed based on the intention-to-treat principle. Results Study Participants Of 1170 individuals who were screened for eligibility, 350 met all eligibility criteria and 184 were enrolled . Of these 184 patients, all but 3 finished the study. The placebo and amantadine organizations were well matched with respect to main demographic variables and prognostic elements, including the DRS score at baseline, interval between enrollment and injury, and analysis at enrollment .